SCOPUS 정보 검색 플랫폼

NDT Plus

Volumn 2, Issue 1, 2009, Pages 36-39

Progressive bevacizumab-associated renal thrombotic microangiopathy

(4) Uy, Alice L a Simper, Novae B a Champeaux, Anne L a Perkins, Robert M a

a MADIGAN ARMY MEDICAL CENTER (United States)

Author keywords

Bevacizumab; Renal failure; Thrombotic microangiopathy; VEGF inhibitor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; PACLITAXEL;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY BIOPSY; OVARY CANCER; PRIORITY JOURNAL; PROTEINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS;

EID: 58449132320 PISSN: 17530784 EISSN: 17530792 Source Type: Journal
DOI: 10.1093/ndtplus/sfn168 Document Type: Article

Times cited : (17)

References (9)

1
- 20544455330
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
- Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-335
- (2005) Biochem Biophys Res Commun , vol.333 , pp. 328-335
- Ferrara, N.¹ Hillan, K.J.² Novotny, W.³

2
- 24744466384
- Bevacizumab - current status and future directions
- Midgley R, Kerr D. Bevacizumab - current status and future directions. Ann Oncol 2005; 16: 999-1004
- (2005) Ann Oncol , vol.16 , pp. 999-1004
- Midgley, R.¹ Kerr, D.²

3
- 34447635695
- Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension
- Izzedine H, Rixe O, Billemont B et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007; 50: 203-218
- (2007) Am J Kidney Dis , vol.50 , pp. 203-218
- Izzedine, H.¹ Rixe, O.² Billemont, B.³

4
- 33846484966
- Renal thrombotic microangiopathy caused by anti-VEGF antibody treatment for metastatic renal-cell carcinoma
- Frangié C, Lefaucheur C, Jacquot C et al. Renal thrombotic microangiopathy caused by anti-VEGF antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8: 177-178
- (2007) Lancet Oncol , vol.8 , pp. 177-178
- Frangié, C.¹ Lefaucheur, C.² Jacquot, C.³

5
- 34247597779
- Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma
- Roncone D, Satoskar A, Nadasdy T et al. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Clin Pract Nephrol 2007; 3: 287-293
- (2007) Clin Pract Nephrol , vol.3 , pp. 287-293
- Roncone, D.¹ Satoskar, A.² Nadasdy, T.³

6
- 34447520277
- Thrombotic microangiopathy and anti-VEGF agents
- Izzedine H, Brocheriou I, Deray G et al. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2007; 22: 1481-1482
- (2007) Nephrol Dial Transplant , vol.22 , pp. 1481-1482
- Izzedine, H.¹ Brocheriou, I.² Deray, G.³

7
- 40849130173
- VEGF inhibition and renal thrombotic microangiopathy
- Eremina V, Jefferson J, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136
- (2008) N Engl J Med , vol.358 , pp. 1129-1136
- Eremina, V.¹ Jefferson, J.² Kowalewska, J.³

8
- 0029024101
- The hemolytic uremic syndrome
- Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int 1995; 48: 2-19
- (1995) Kidney Int , vol.48 , pp. 2-19
- Remuzzi, G.¹ Ruggenenti, P.²

9
- 58449134269
- Accessed 10/28/2008
- Avastin (bevacizumab) labeling information. http://www.fda.gov/cder/foi/ label/2008/125085s91lbl.pdf. Accessed 10/28/2008
- Avastin (bevacizumab) labeling information

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.